Status Epilepticus Colloquia

Status Epilepticus Colloquia

The London-Innsbruck Colloquia on Status Epilepticus and Acute seizures are a series of biannual international conferences organized by Simon Shorvon (UCL, London) and Eugen Trinka (Paracelsus University, Salzburg) between 2007-2019:

– 1st Colloquium 2007 – London
– 2nd Colloquium 2009 – Innsbruck
– 3rd Colloquium 2011 – Oxford
– 4th Colloquium 2013 – Salzburg
– 5th Colloquium 2015 – London
– 6th Colloquium 2017 – Salzburg
– 7th Colloquium 2019 – London

Over this 12-year period, much has developed in the field of Status Epilepticus, which has become one of the fastest growing topics in the whole of epilepsy. This is reflected in the 6882 publications listed in Pubmed over this period, more than were published in all the previous years on the Pubmed index. During this time, a number of new advances were made which were presented and discussed at the Colloquia, which have become an important landmark in the scientific and clinical epilepsy calendar.

At the 2017 colloquium, the following advances in the previous 10 years were highlighted:

Basic science: The basic science understanding of the mechanisms and also the consequences of status epilepticus has advanced considerably with advances in receptor trafficking, cerebral inhibition at a cellular and system’s level, synaptic function, molecular genetics, epigenetics, and experimental pharmacology. This progress in understanding of the mechanisms responsible for the failure for seizure suppression and seizure perpetuation led to new concepts in definition of status and the development of new drugs medicines for different stages of status epilepticus.

Epidemiology: In the field of epidemiology, there have bee now good estimates of frequency of refractory and super-refractory status epilepticus (SRSE). The ageing population will lead to an increase in the incidence of status epilepticus.

Clinical: There have been a range of new measures to predict outcome and measures of severity which have been validated and used across different countries. There have been studies of the range of uncommon causes of status epilepticus, including genetic causes, and both clinical and pathological studies of auto-immune and mitochondrial cases. The entity of SRSE has been defined and the concept has attracted wide usage.

Electroencephalography: The EEG patterns of nonconvulsive status epilepticus (NCSE) have been better understood and the Salzburg Criteria for defining NCSE have been widely accepted.

Treatment: The advances in the use of benzodiazepine therapies ‘out of hospital’ using different routes of administration have been perhaps the most important public health advances in the whole of epilepsy. There have also been, for the first time RCTs in the field of established status. New treatment protocols, new drugs, and new types of treatment especially in SRSE, include ketamine, lacosamide, brivaracetam, and neurosteroids, such as ganaxolone or allopregnanolone.  The better appreciation of the risks and the benefits of anaesthesia led to the development of appropriate treatment protocols.

7th Colloquium on Status Epilepticus and Acute Seizures – April 7-9 2019:
The venue of the Colloquium is the Francis Crick Institute, in the centre of London (adjacent to the Eurostar terminal at St Pancras Station). This biomedical discovery institute is devoted to understanding the fundamental biology underlying health and disease, in a spectacular new building opened in 2016, and is founded by the Medical Research Council (MRC), Cancer Research UK, Wellcome Trust, and three leading London university Colleges – UCL, Imperial College and King’s College (see https://www.crick.ac.uk/about-us/). The faculty includes the leading figures in the field of Status Epilepticus and Acute Seizures from around the world.

The programme, registration details and other information are to be found on: https://www.statusepilepticus.eu/